- Home
- ALLO vs RA Comparison
ALLO vs RA Comparison
Compare ALLO & RA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLO | RA |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.1M | 712.8M |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ALLO | RA |
|---|---|---|
| Price | $2.02 | $12.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $8.35 | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 158.0K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $12.50 |
| 52 Week High | $4.46 | $13.59 |
Technical Indicators
Market Signals| Indicator | ALLO | RA |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 43.47 |
| Support Level | $1.87 | $12.51 |
| Resistance Level | $2.25 | $13.02 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 38.71 | 38.67 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. The investment objective of the Fund is to seek high total return, through high current income and secondarily, through growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities, Infrastructure Securities, and Natural Resources Securities. The Fund operates in a single operating segment.